Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Non-cash Items (2024 - 2026)

ArriVent BioPharma has reported Non-cash Items over the past 3 years, most recently at $2.0 million for Q1 2026.

  • Quarterly results put Non-cash Items at $2.0 million for Q1 2026, up 93.92% from a year ago — trailing twelve months through Mar 2026 was $2.0 million (up 93.92% YoY), and the annual figure for FY2025 was $31.7 million, up 4269.36%.
  • Non-cash Items reached $2.0 million in Q1 2026 per AVBP's latest filing, down from $31.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $33.0 million in Q1 2024 and bottomed at $630058.0 in Q3 2024.
  • Median Non-cash Items over the past 3 years was $1.2 million (2025), compared with a mean of $11.0 million.
  • Peak annual rise in Non-cash Items hit 4419.43% in 2025, while the deepest fall reached 96.89% in 2025.
  • Over 3 years, Non-cash Items stood at $724934.0 in 2024, then skyrocketed by 4269.36% to $31.7 million in 2025, then crashed by 93.73% to $2.0 million in 2026.
  • Business Quant data shows Non-cash Items for AVBP at $2.0 million in Q1 2026, $31.7 million in Q4 2025, and $28.5 million in Q3 2025.